[{"id":"a7c4f9e4-84af-4d2b-9a47-edc69ca3a38e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07476729","created_at":"2026-03-28T01:40:41.936Z","updated_at":"2026-03-28T01:40:41.936Z","phase":"Phase 3","brief_title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","source_id_and_acronym":"NCT07476729","lead_sponsor":"Charite University, Berlin, Germany","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 03/31/2033","primary_completion_date":" 03/31/2033","study_txt":" Completion: 03/31/2033","study_completion_date":" 03/31/2033","last_update_posted":"2026-03-17"},{"id":"2224e4ab-560d-46f1-b752-7b1d2154770f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04240808","created_at":"2021-01-18T20:37:11.481Z","updated_at":"2025-02-25T12:37:29.775Z","phase":"Phase 1","brief_title":"Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)","source_id_and_acronym":"NCT04240808","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCD19 CAR T Cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-24"},{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"48054460-bb4c-4bdd-a42b-f1e76f7803ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586478","created_at":"2021-01-18T21:52:51.200Z","updated_at":"2025-02-25T16:32:17.231Z","phase":"Phase 2","brief_title":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04586478","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"facf7f83-63bf-49f3-a6fb-2b75c0782dba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05848687","created_at":"2023-05-08T15:04:02.177Z","updated_at":"2025-02-25T17:26:10.730Z","phase":"Phase 1/2","brief_title":"TINI 2: Total Therapy for Infants with Acute Lymphoblastic Leukemia II","source_id_and_acronym":"NCT05848687","lead_sponsor":"Tanja Andrea Gruber","biomarkers":" KMT2A","pipe":" | ","alterations":" CD19 positive","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • Komzifti (ziftomenib) • mercaptopurine"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2025-01-31"},{"id":"50180a34-f827-4af8-ae52-29b514c2e08b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03512405","created_at":"2021-01-18T17:17:18.091Z","updated_at":"2025-02-25T17:36:00.408Z","phase":"Phase 1/2","brief_title":"Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03512405","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" CD19 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/02/2019","start_date":" 08/02/2019","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2025-01-29"},{"id":"2a05375a-5452-4690-a731-769e2628d4de","acronym":"TRANSCEND-CLL-004","url":"https://clinicaltrials.gov/study/NCT03331198","created_at":"2021-01-18T16:27:01.921Z","updated_at":"2024-07-02T16:34:59.670Z","phase":"Phase 1/2","brief_title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT03331198 - TRANSCEND-CLL-004","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" PLCG2 • CD5","pipe":" | ","alterations":" CD19 positive • PLCG2 mutation","tags":["PLCG2 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 209","initiation":"Initiation: 11/27/2017","start_date":" 11/27/2017","primary_txt":" Primary completion: 11/26/2027","primary_completion_date":" 11/26/2027","study_txt":" Completion: 11/26/2027","study_completion_date":" 11/26/2027","last_update_posted":"2024-05-31"},{"id":"97131464-120c-4497-92ac-88a2fa5c808a","acronym":"AMC-112","url":"https://clinicaltrials.gov/study/NCT05077527","created_at":"2021-10-14T19:57:31.317Z","updated_at":"2024-07-02T16:35:03.833Z","phase":"Phase 1","brief_title":"Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05077527 - AMC-112","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":" | ","alterations":" CD19 positive","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/20/2024","start_date":" 07/20/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-05-14"},{"id":"52d33ddf-12db-4781-8289-d23be5e18186","acronym":"CYTB323A12101","url":"https://clinicaltrials.gov/study/NCT03960840","created_at":"2021-01-18T19:29:26.737Z","updated_at":"2024-07-02T16:35:06.077Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL","source_id_and_acronym":"NCT03960840 - CYTB323A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-05-03"},{"id":"494a3a47-09dc-456f-a62d-fc7e845bfb64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016377","created_at":"2021-01-18T14:50:40.602Z","updated_at":"2024-07-02T16:35:08.102Z","phase":"Phase 1/2","brief_title":"Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL","source_id_and_acronym":"NCT03016377","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ABL1 • BCR • CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["ABL1 • BCR • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • iC9-CAR19 cells • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/22/2012","start_date":" 03/22/2012","primary_txt":" Primary completion: 04/22/2026","primary_completion_date":" 04/22/2026","study_txt":" Completion: 04/22/2041","study_completion_date":" 04/22/2041","last_update_posted":"2024-04-23"},{"id":"3acef521-8452-44ff-9dd7-afcb4027064e","acronym":"SAGAN","url":"https://clinicaltrials.gov/study/NCT01853631","created_at":"2021-01-18T08:16:40.054Z","updated_at":"2024-07-02T16:35:11.914Z","phase":"Phase 1","brief_title":"Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)","source_id_and_acronym":"NCT01853631 - SAGAN","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2036","study_completion_date":" 02/01/2036","last_update_posted":"2024-04-02"},{"id":"92a6a0af-b961-4dcd-9f55-a9a03ecbdb52","acronym":"TRANSCEND-NHL-001","url":"https://clinicaltrials.gov/study/NCT02631044","created_at":"2021-01-17T17:40:23.377Z","updated_at":"2024-07-02T16:35:12.562Z","phase":"Phase 1","brief_title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","source_id_and_acronym":"NCT02631044 - TRANSCEND-NHL-001","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14) • BCL6 rearrangement • CCND1 expression • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 387","initiation":"Initiation: 01/06/2016","start_date":" 01/06/2016","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 05/10/2024","study_completion_date":" 05/10/2024","last_update_posted":"2024-03-27"},{"id":"7087c1cd-d2b0-4a2d-b876-81f1fb3057ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT04827745","created_at":"2022-04-25T15:54:32.118Z","updated_at":"2024-07-02T16:35:14.318Z","phase":"Phase 2","brief_title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","source_id_and_acronym":"NCT04827745","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD81","pipe":" | ","alterations":" CD19 positive","tags":["CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-18"},{"id":"48501323-09cb-4f5b-a243-32ead55180fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05370547","created_at":"2022-05-11T15:55:57.619Z","updated_at":"2024-07-02T16:35:16.239Z","phase":"Phase 1/2","brief_title":"Chidamide Bridging for CAR-T Therapy","source_id_and_acronym":"NCT05370547","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • BCL6 • PMAIP1","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • PMAIP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Epidaza (chidamide) • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"b244d21b-7ca6-459d-808a-603983ee64ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03233854","created_at":"2021-01-18T15:58:49.473Z","updated_at":"2024-07-02T16:35:17.505Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT03233854","lead_sponsor":"Crystal Mackall, MD","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-02-28"},{"id":"56e85ac1-baa8-4eea-9968-8885e7529381","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779930","created_at":"2023-03-22T14:03:05.684Z","updated_at":"2024-07-02T16:35:20.009Z","phase":"Phase 1","brief_title":"Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL","source_id_and_acronym":"NCT05779930","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-02-09"},{"id":"2beab5d7-ecc5-4e48-96b1-5c44eb70d853","acronym":"UHKT-CAR19-01","url":"https://clinicaltrials.gov/study/NCT05054257","created_at":"2021-09-23T17:53:00.619Z","updated_at":"2024-07-02T16:35:24.509Z","phase":"Phase 1","brief_title":"CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05054257 - UHKT-CAR19-01","lead_sponsor":"Institute of Hematology and Blood Transfusion, Czech Republic","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/02/2021","start_date":" 06/02/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-01-04"},{"id":"8006740b-2d06-4b2c-ab89-24e67ff05c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420493","created_at":"2022-06-15T15:55:29.040Z","updated_at":"2024-07-02T16:35:24.497Z","phase":"Phase 1","brief_title":"Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05420493","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-01-04"},{"id":"b9c68d27-6990-4a0a-a0ac-3074641ed5c2","acronym":"MB106-CD20-001","url":"https://clinicaltrials.gov/study/NCT05360238","created_at":"2022-05-05T01:55:24.129Z","updated_at":"2024-07-02T16:35:25.644Z","phase":"Phase 1/2","brief_title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","source_id_and_acronym":"NCT05360238 - MB106-CD20-001","lead_sponsor":"Mustang Bio","biomarkers":" BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-106"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-20"},{"id":"c96af201-1fe0-41f1-9d48-5df4a19900bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919526","created_at":"2021-01-18T19:17:14.730Z","updated_at":"2024-07-02T16:35:26.713Z","phase":"Phase 1","brief_title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","source_id_and_acronym":"NCT03919526","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/11/2019","start_date":" 08/11/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-12-08"},{"id":"07666392-68d5-4fad-ae36-30e09480e5ad","acronym":"OUTREACH","url":"https://clinicaltrials.gov/study/NCT03744676","created_at":"2021-01-18T18:20:28.707Z","updated_at":"2024-07-02T16:35:26.939Z","phase":"Phase 2","brief_title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","source_id_and_acronym":"NCT03744676 - OUTREACH","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Breyanzi (lisocabtagene maraleucel)"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 11/29/2018","start_date":" 11/29/2018","primary_txt":" Primary completion: 09/22/2023","primary_completion_date":" 09/22/2023","study_txt":" Completion: 09/22/2023","study_completion_date":" 09/22/2023","last_update_posted":"2023-12-06"},{"id":"6a4eb48f-d80a-4473-8435-28c248997a37","acronym":"","url":"https://clinicaltrials.gov/study/NCT05222438","created_at":"2022-02-05T18:29:17.280Z","updated_at":"2024-07-02T16:35:30.883Z","phase":"Phase 2","brief_title":"Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant","source_id_and_acronym":"NCT05222438","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-01"},{"id":"ddab7878-bbd6-408a-871f-fa049fe36f03","acronym":"CARTHEDRALL","url":"https://clinicaltrials.gov/study/NCT06101381","created_at":"2023-10-26T15:14:01.501Z","updated_at":"2024-07-02T16:35:31.635Z","phase":"Phase 1/2","brief_title":"CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma","source_id_and_acronym":"NCT06101381 - CARTHEDRALL","lead_sponsor":"University of Sao Paulo","biomarkers":" BCL2","pipe":" | ","alterations":" CD19 positive • MYC rearrangement • CD19 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • MYC rearrangement • CD19 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2023-10-26"}]